Posts

Trigeminal Autonomic Cephalgias (TACs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Trigeminal Autonomic Cephalgias (TACs) Market Outlook Thelansis’s “Trigeminal Autonomic Cephalgias (TACs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Trigeminal Autonomic Cephalgias (TACs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Trigeminal Autonomic Cephalgias (TACs) Overview Trigeminal autonomic cephalgias (TACs) are a distinct group of primary headache disorders characterised by strictly unilateral, severe trigeminal distribution pain invariably accompanied by ipsilateral cranial autonomic features — lacrimation, conjunctival injection, rhinorrhoea, ptosis, and eyelid oedema — reflecting activation of the tri...
Post a Comment
Read more

Stiff-Person Syndrome (SPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Stiff-Person Syndrome (SPS) Market Outlook Thelansis’s “Stiff-Person Syndrome (SPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stiff-Person Syndrome (SPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Stiff-Person Syndrome (SPS) Overview Stiff-person syndrome (SPS) is a rare, debilitating autoimmune CNS disorder characterised by progressive muscle rigidity, episodic painful spasms, and heightened sensitivity to external stimuli — noise, touch, and emotional stress — resulting from autoimmune disruption of GABAergic inhibitory neurotransmission within the spinal cord and brainstem. The pathophysiology is predominantl...
Post a Comment
Read more

Relapsed or Refractory Mantle Cell Lymphoma (MCL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Relapsed or Refractory Mantle Cell Lymphoma (MCL) Market Outlook Thelansis’s “Relapsed or Refractory Mantle Cell Lymphoma (MCL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Mantle Cell Lymphoma (MCL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory Mantle Cell Lymphoma (MCL) Overview Relapsed or refractory mantle cell lymphoma (r/r MCL) is an aggressive B-cell lymphoma arising from cyclin D1-overexpressing mature B-cells — driven by the hallmark t(11;14) chromosomal translocation juxtaposing CCND1 and IGH loci — with relapsed or refractory disease representing a clinically ch...
Post a Comment
Read more

Charcot-Marie-Tooth (CMT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Charcot-Marie-Tooth (CMT) Market Outlook Thelansis’s “Charcot-Marie-Tooth (CMT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth (CMT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Charcot-Marie-Tooth (CMT) Overview Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, encompassing a clinically and genetically heterogeneous group of disorders caused by mutations across numerous genes regulating peripheral nerve myelination and axonal integrity — most prevalently PMP22 duplication causing CMT1A, GJB1 mutations causing X-linked CMTX, and MPZ and MFN2 mutations underlying d...
Post a Comment
Read more

Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Market Outlook Thelansis’s “Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Overview Relapsed or refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL) encompasses a heterogeneous group of lymphoid malignancies — including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma — that recur or fail to achieve remission follow...
Post a Comment
Read more

Cystic Fibrosis (CF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Cystic Fibrosis (CF) Market Outlook Thelansis’s “Cystic Fibrosis (CF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cystic Fibrosis (CF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Cystic Fibrosis (CF) Overview Cystic fibrosis (CF) is a life-limiting autosomal recessive multisystem disorder caused by mutations in the CFTR gene — encoding the cystic fibrosis transmembrane conductance regulator chloride channel — resulting in defective epithelial ion transport, viscous secretion accumulation, and progressive organ damage predominantly affecting the lungs, pancreas, liver, and reproductive tract. Over 2,000 CFTR mutatio...
Post a Comment
Read more

Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Market Outlook Thelansis’s “Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced or Metastatic Adenoid Cystic Carcinoma (ACC) Overview Advanced or metastatic adenoid cystic carcinoma (ACC) is a rare, slow-growing but relentlessly progressive malignancy arising predominantly from salivary glands — major and minor — and occasionally from lacrimal glands, tracheobronchial tree, and breast, characterised by insidious...
Post a Comment
Read more